



Review

Critical practical aspects in the application of liquid chromatography–mass spectrometric studies for the characterization of impurities and degradation products

Mallikarjun Narayanam, Tarun Handa¹, Parul Sharma¹, Shalu Jhajra¹, Praveen Kumar Muthe¹, Pavan Kumar Dappili¹, Ravi P. Shah², Saranjit Singh^{*}

Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar 160062, Punjab, India

ARTICLE INFO

Article history:

Received 10 April 2013

Accepted 18 April 2013

Available online 28 April 2013

Keywords:

Impurities

Degradation products

Characterization

Strategy

Practical aspects

LC–MS

ABSTRACT

Liquid chromatography–mass spectrometry (LC–MS) is considered today as a mainstay tool for the structure characterization of minor components like impurities (IMPs) and degradation products (DPs) in drug substances and products. A multi-step systematic strategy for the purpose involves high resolution mass and multi-stage mass studies on both the drug and IMPs/DPs, followed by comparison of their fragmentation profiles. Its successful application requires consideration of many practical aspects at each step. The same are critically discussed in this review.

© 2013 Elsevier B.V. All rights reserved.

Abbreviations: [M+H]⁺, molecular ion; 2-MeTHF, 2-methyltetrahydrofuran; 2NFP-APB, [3-(2-nitro-4-trifluoromethylphenyl) aminophenyl] dihydroxyborane; 4-APEBA, 4-(2-((4-bromophenethyl) dimethylammonio) ethoxy) benzenaminium dibromide; AAPH, 2,2'-azobis(2-amidinopropane) dihydrochloride; ACN, acetonitrile; AIBN, azobisisobutyronitrile; AMSDA, 2-acrylamino-2-methyl-propanesulfonic acid; APCI, atmospheric pressure chemical ionization; API, atmospheric pressure ionization; APPI, atmospheric pressure photoionization; APZ, 4-(4-methyl-1-piperazyl)-3-nitrobenzoyl azide; BMC, 4-bromomethyl-7-methoxycoumarin; CHEFOG, chemical formula generator; CID, collision-induced dissociation; Da, Dalton; DAABD-AE, 4-[2-(N,N-dimethylamino) ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole; DAABD-MHz, 4-[2-(N,N-dimethylamino) ethylaminosulfonyl]-7-N-methylhydrazino-2,1,3-benzoxadiazole; DAPB, dansyl-3-aminophenylboronic acid; DBA, di-n-butyl amine; DCU, dicyclohexyl urea; DFT, density functional theory; DIPEA, diisopropylethylamine; DMAE, 2-(N,N-dimethyl-amino) ethyl acrylate; DMAP, dimethyl amino pyridine; DMEQTAD, 4-[2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalyl)ethyl]-1,2,4-triazoline-3,5-dione; DMF, dimethylformamide; DMIS, 1,2-dimethylimidazole-4-sulfonyl; DMSO, dimethyl sulfoxide; DNPH, 2,4-dinitrophenylhydrazine; Dns-Cl, dansyl chloride; Dns-Hz, dansyl hydrazine; DPs, degradation products; ESI, electrospray ionization; ESI-MS, electrospray ionization-mass spectrometry; ESI-MS/TOF, electrospray ionization mass spectrometry/time of flight; FT-ICR, fourier transform-ion cyclotron resonance; GirP, 1-(carboxymethyl) pyridium chloride hydrazide; GirT, 1-(carboxymethyl) trimethylammonium chloride hydrazide; H/D, hydrogen/deuterium; HILIC, hydrophilic interaction liquid chromatography; HMP, 2-hydrazino-1-methyl-pyridine; HP, 2-hydrazinopyridine; HPLC, high performance liquid chromatography; HRMS, high resolution mass spectrometry; IHD, index of hydrogen deficiency; IMPs, impurities; IR, infrared; IUPAC, International Union of Pure and Applied Chemistry; LC, liquid chromatography; LC-ESI-MS, liquid chromatography-electrospray ionization-mass spectrometry; LC-MS, liquid chromatography-mass spectrometry; LOQ, limit of quantification; MBO-TAD, 4-[4-(6-methoxy-2-benzoxazolyl) phenyl]-1,2,4-triazoline-3,5-dione; MDMAES, mono(dimethylaminoethyl) succinyl imidazolidine; mM, millimolar; mmu, milli mass unit; MNBDH, N-methyl-4-hydrazino-7-nitrobenzofurazan; MS, mass spectrometry; MS-TOF, mass spectrometry-time of flight; MSⁿ, multi stage mass spectrometry; NA, isonicotinoyl azide; NBA, 2-nitrobenzaldehyde; NBD-Cl, 7-chloro-4-nitro-2,1,3-benzoxadiazole; NBD-F, 7-fluoro-4-nitro-2,1,3-benzoxadiazole; NBDPZ, 4-nitro-7-piperazino-2,1,3-benzoxadiazole; NFPH, 2-nitro-4-trifluoromethylphenylhydrazine; NH₄OH, ammonium hydroxide; NIT, naphthylisothiocyanate; NMR, nuclear magnetic resonance; NPTAD, 4-(4-nitrophenyl)-1,2,4-triazoline-3,5-dione; NSAIDs, non-steroidal anti-inflammatory drugs; PABA, para-amino benzoic acid; PAHs, polycyclic aromatic hydrocarbons; PBS, 4-(1H-pyrazol-1-yl) benzenesulfonyl; PFB-Br, pentafluorobenzyl bromide; PFPA, pentafluoropropionic acid anhydride; PGF2α, prostaglandin F2α; ppm, parts per million; PPZ, 1-(2,4-dinitro-5-fluorophenyl)-4-methylpiperazine; PS, pyridine-3-sulfonyl; Q-TOF, quadrupole-time of flight; RDB, ring plus double bonds; RP-HPLC, reversed phase-high performance liquid chromatography; SRM, selected reaction monitoring; TFA, trifluoroacetic acid; TFE, 2,2,2-trifluoroethanol; THAS, 4-(trimethylammonium) anilyl-N-hydroxysuccinimidyl carbamate iodide; THF, tetrahydrofuran; TMAE, trimethyl amino-ethylalcohol; TMPP, tris(2,4,6-trimethoxyphenyl) phosphine; TMPP-AcPFP, S-pentafluorophenyl tris(2,4,6-trimethoxyphenyl) phosphonium acetate bromide; TMPP-PrG, (4-hydrazino-4-oxobutyl) tris(2,4,6-trimethoxyphenyl) phosphonium bromide; TOF, time of flight; TSH, p-toluenesulfonylhydrazide; UV, ultra violet; XRD, X-ray Diffraction.

^{*} Corresponding author at: Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar 160062, Punjab, India. Tel.: +91 172 2292031; fax: +91 172 2214692.

E-mail address: ssingh@niper.ac.in (S. Singh).

¹ These authors contributed equally.

² Present address: Biocon Bristol Myers-Squibb Research and Development Center (BBRC), Biocon Park, Bengaluru, India.

Contents

1. Introduction	192
2. Strategy for the characterization of impurities/degradation products by mass spectrometric approaches	193
3. Practical issues in sample preparation, method development and instrument settings	194
3.1. Preparation and handling of drug samples for direct infusion	194
3.2. Handling of samples containing impurities and degradation products	194
3.3. Important considerations during LC method development	194
3.3.1. Mobile phase components	194
3.3.2. Mobile phase pH and analyte pK_a	195
3.3.3. Flow rate	195
3.4. Selection of ionization source and polarity	196
3.4.1. Ionization source	196
3.4.2. Positive and negative polarity	196
3.5. Calibration and tuning of mass instrument for accurate and precise results	196
3.5.1. Calibration and tuning	196
3.6. Contamination of mass system and its avoidance	197
3.7. Optimization of instrument parameters	198
4. Acquisition and analyses of mass spectra	198
4.1. Molecular ion spectra and molecular mass determination	198
4.1.1. Searching based on potential structures	198
4.1.2. Identification through the presence of adducts	199
4.1.3. Promotion of adduct formation, derivatization, etc.	200
4.2. Acquisition and interpretation of fragment spectrum	200
4.2.1. Generation of the fragment spectrum	200
4.2.2. Interpretation of the fragment spectrum	200
4.3. Accurate mass data and elemental composition	201
4.4. Nitrogen rule, ring plus double bonds and calculation of mass error	202
4.4.1. Nitrogen rule	202
4.4.2. Ring plus double bonds (RDB)	202
4.4.3. Calculation of mass error	203
4.5. Consideration of isotopic abundance	203
4.6. Multi-stage mass spectrometry data	204
4.7. H/D exchange data	205
5. Compilation of experimental and derived data	208
6. Establishing fragmentation pathways	208
6.1. Important considerations before outlining of fragmentation pathways in API ionization sources	208
6.2. Important losses and rearrangements during mass fragmentations in API sources	209
6.3. Outlining of fragmentation pathways	209
7. Comparison of fragmentation pathways of drug and impurities/degradation products	212
8. Confirmation of the proposed structures through mechanistic explanation	213
9. Limitations of mass spectrometry for unequivocal characterization of unknown structures	213
10. Conclusion	214
Acknowledgment	214
Appendix A. Supplementary data	214
References	214

1. Introduction

The definition of quality of pharmaceuticals has changed in recent times. From previous focus on purity, a greater emphasis is being paid today on impurities (IMPs), degradation products (DPs), etc. The characterization of such trace to minor analytes is not only important during drug and product development, but also from the perspective of regulatory approvals. Fortunately, the advent of a variety of sophisticated hyphenated techniques has made this task much simpler [1], against the time-consuming exercise involving isolation and enrichment of targeted compounds to milligram quantities, followed by acquisition of the spectral (mass, UV, NMR and IR) and elemental (CHN) data. In particular, liquid chromatography–mass spectrometry (LC–MS) is a technique of choice among all other hyphenated techniques due to its sensitivity and ease of use. Also, it carries potential in itself to provide unequivocal characterization of the structure of most trace to minor components, except enantiomers and epimers. A variety of LC–MS instruments are available today, which vary in (i) atmospheric pressure ionization (API) sources, like electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI) and/or atmospheric pressure photo ionization (APPI); and (ii) analyzers, like

quadrupole, ion trap, time of flight (TOF), Orbitrap, etc. Usually ESI and APCI interfaces along with ion trap, TOF and Orbitrap analyzers are more useful for providing qualitative information on component structures.

The unequivocal structure elucidation of unknown analytes by LC–MS techniques is possible through the strategy put forth by us earlier [1,2]. It entails the generation of molecular ion and fragment spectra of both the drug and its related substances; determination of their accurate and exact masses, elemental formula, ring plus double bonds and number of nitrogens; determination of the number of labile hydrogens through hydrogen/deuterium (H/D) exchange mass studies; MS^n study on molecular ions and fragments, and establishment of fragmentation pathways, followed by their comparison. Introductory details on each of these steps were provided by us in our previous publication [1]. The strategy has been duly validated in our laboratories and even by other researchers by application to the characterization of process impurities [3], drug degradation products [4–6], drug–drug interaction products [7,8], drug–excipient interaction products [9], and metabolites of a variety of drugs [10,11].

Download English Version:

<https://daneshyari.com/en/article/1220874>

Download Persian Version:

<https://daneshyari.com/article/1220874>

[Daneshyari.com](https://daneshyari.com)